Loading
Life sciences · Journal article
Behavioral Sciences · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Public and patient interest in psychedelic-assisted psychotherapy is increasing, but people seeking access to psychedelic trials may be more clinically heterogeneous than the populations these trials can enrol. We conducted a cross-sectional descriptive analysis of previously unreported aggregate telephone-screening data from the coordinating site of PRIDE, an ongoing Italian multicentre phase II randomized trial comparing psilocybin with personalized neuromodulation for treatment-resistant depression (TRD). Among 67 candidates screened between November 2025 and June 2026, 54 were excluded (80.6%), eight were enrolled and treated (11.9%), and five were preliminarily eligible (7.5%). The leading reason for exclusion was absence of protocol-defined TRD or another psychiatric diagnosis (27/54, 50.0%), followed by age outside the protocol range (18.5%), current suicidal or self-harm ideation (13.0%), and substance use disorder or dependence (9.3%). The diagnostic diversity of excluded candidates highlights the gap between a narrowly defined trial population and heterogeneous treatment-seeking individuals. These screening data do not address treatment response or individualized treatment selection, but they help contextualize recruitment yield and the external validity of psychedelic trials. Trial registration: Clinical Trials Information System, EU CT No. 2024-519844-34-03.